|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3910 USD | -7.46% |
|
-3.56% | -70.27% |
| Capitalization | 422M 366M 344M 313M 574M 36.46B 649M 4.02B 1.57B 16.66B 1.58B 1.55B 61.28B | P/E ratio 2025 * |
-0.54x | P/E ratio 2026 * | -2.82x |
|---|---|---|---|---|---|
| Enterprise value | 658M 571M 536M 487M 894M 56.78B 1.01B 6.25B 2.44B 25.94B 2.47B 2.42B 95.42B | EV / Sales 2025 * |
0.77x | EV / Sales 2026 * | 0.74x |
| Free-Float |
95.31% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Tilray Brands, Inc.
More recommendations
More press releases
More news
| 1 day | -7.46% | ||
| 1 week | -3.56% | ||
| Current month | -7.12% | ||
| 1 month | -20.12% | ||
| 3 months | -38.65% | ||
| 6 months | -67.05% | ||
| Current year | -70.27% |
| 1 week | 0.4 |  | 0.46 |
| 1 month | 0.37 | | 0.49 |
| Current year | 0.37 | | 1.51 |
| 1 year | 0.37 | | 2.15 |
| 3 years | 0.37 | | 5.12 |
| 5 years | 0.37 | | 23.04 |
| 10 years | 0.37 | | 23.04 |
| Manager | Title | Age | Since |
|---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 66 | 30/04/2021 |
Carl Merton
DFI | Director of Finance/CFO | 56 | 30/04/2021 |
Roger Savell
ADM | Chief Administrative Officer | 63 | 30/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Irwin Simon
CHM | Chairman | 66 | 30/04/2021 |
Jodi Butts
BRD | Director/Board Member | 53 | 30/04/2021 |
David Clanachan
BRD | Director/Board Member | 63 | 29/04/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.46% | -3.56% | -76.60% | -87.29% | 422M | ||
| -1.62% | +3.00% | -9.96% | +176.63% | 725B | ||
| -1.08% | -1.06% | +5.23% | -9.70% | 373B | ||
| -2.03% | -6.12% | -50.23% | +31.32% | 344B | ||
| -2.04% | -0.99% | +10.38% | +34.60% | 337B | ||
| -0.49% | -3.04% | +6.56% | -13.81% | 260B | ||
| -0.83% | -2.05% | +2.17% | +20.65% | 233B | ||
| -1.44% | -1.02% | -14.21% | +9.24% | 228B | ||
| -2.28% | -0.03% | -37.80% | -6.57% | 203B | ||
| -1.16% | +1.03% | -3.40% | +26.99% | 159B | ||
| Average | -2.04% | +1.50% | -16.79% | +18.21% | 286.28B | |
| Weighted average by Cap. | -1.47% | +2.15% | -9.89% | +53.48% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 850M 738M 692M 630M 1.16B 73.4B 1.31B 8.08B 3.15B 33.54B 3.19B 3.12B 123B | 905M 785M 737M 671M 1.23B 78.15B 1.39B 8.61B 3.36B 35.71B 3.4B 3.32B 131B |
| Net income | -653M -567M -532M -484M -889M -56.42B -1B -6.21B -2.43B -25.78B -2.45B -2.4B -94.82B | -100M -87.16M -81.81M -74.42M -137M -8.67B -154M -955M -373M -3.96B -377M -369M -14.58B |
| Net Debt | 235M 204M 192M 174M 320M 20.32B 362M 2.24B 873M 9.28B 883M 864M 34.14B | 248M 215M 202M 184M 338M 21.44B 382M 2.36B 921M 9.8B 932M 912M 36.03B |
More financial data
* Estimated data
Employees
2,650
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/06/25 | 0.3954 $ | -6.41% | 13,600,777 |
| 16/06/25 | 0.4225 $ | +4.58% | 16,456,305 |
| 13/06/25 | 0.4040 $ | -2.95% | 11,232,637 |
| 12/06/25 | 0.4163 $ | -2.23% | 16,941,555 |
| 11/06/25 | 0.4258 $ | +1.45% | 45,357,991 |
Delayed Quote Nasdaq, June 17, 2025 at 05:53 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
0.4225USD
Average target price
1.319USD
Spread / Average Target
+212.23%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TLRY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition